A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation. As the interaction promotes elevated plasma LDL-C levels,...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M.G. Princen, James Bonnar, Benny J. Evison
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2022-11-01
Saila:Journal of Lipid Research
Gaiak:
PCSK9
cardiovascular disease
hypercholesterolemia
small-molecule
lipoproteins
apolipoproteins
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S0022227522001262

Internet

http://www.sciencedirect.com/science/article/pii/S0022227522001262

Antzeko izenburuak